Skip to main content
Cosentyx Info

Discover how COSENTYX can help your patients

*Studied in patients since 2007. FDA approved for moderate to severe PsO in adults in 2015, for active PsA and AS in adults in 2016, for active nr-axSpA with objective signs of inflammation in adults in 2020, for moderate to severe PsO in children 6 years and older, active PsA in children 2 years and older, and active ERA in children 4 years and older in 2021, and for moderate to severe HS in adults 2023.1,6
As of December 2023: SC prescriptions across all indications.

*Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.

AS, ankylosing spondylitis; ERA, enthesitis-related arthritis; FDA, US Food and Drug Administration; HS, hidradenitis suppurativa; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; SC, subcutaneous.

1. Data on file. AIN457A2102 Clinical Study Report. Novartis Pharmaceuticals Corp; December 2008. 
2. Data on file. Cosentyx Patient Count and TRx. Novartis Pharmaceuticals Corp; December 2023. 
3. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747-761. 
4. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507-1514. 
5. Food and Drug Administration. Drug trials snapshot: COSENTYX (secukinumab). Accessed June 25, 2023. 
6. Cosentyx FDA approval history. Accessed March 21, 2024.